Outpacing disease at every turn

Research on hematology and oncology is thriving, generating new insights into how best to identify and treat subtypes of disease with cutting-edge therapies. At Danaher, our businesses touch every step of the cancer patient journey, from initial diagnosis to follow-up in remission. 

The worldwide burden of neurodegenerative disease is growing, but so are solutions to combat it. With new therapies for Alzheimer’s finally available, we are working to enable physicians to diagnose the disease and other neurodegenerative conditions – the first step toward treating them.

Patients are often treated with antibiotics without confirming an infection is present or what type of infection it is. Danaher is developing new diagnostics that rapidly identify pathogens and the host response they induce to guide appropriate antibiotic use and lower the potential for antimicrobial resistance. 

In life-or-death situations, precision matters – and so does speed. We are pioneering new ways to characterize critical illness in real time throughout the patient’s stay in the hospital: from the emergency department, through the intensive care unit, operating room or general hospital floor.

With new treatment modalities, such as antibody-drug conjugates in cancer, come new needs for identifying the patients most likely to benefit from the right therapies at the right times. We’re developing technologies that can stratify patient populations based on meaningful measurements.   

The better we can monitor patients for indications of disease recurrence, the earlier we can intervene – and the more precise we can make their treatment.

Our diverse technologies are pushing the barriers of quality of data collection and analytical sensitivity, allowing us to observe, quantify and track biomarkers like never before so we can better understand and treat disease.  

We pursue and combine multiple testing modalities (genomic, proteomic, and tissue-based), prioritize reproducibility, and responsibly leverage bioinformatics and AI to allow for the creation of complex, multi-analyte assays.

With industry-leading technologies already in use in laboratories around the world, our innovations can be implemented almost immediately for faster solutions on trusted systems.

Generative and predictive AI, data integration, and knowledge generation are revolutionizing healthcare – and diagnostics are no exception. We’re leveraging current capabilities and building new ones to put digital tech to work for healthcare providers and patients. 

Inventing new technologies isn’t enough. We also  work with key partners in the innovation ecosystem to overcome barriers to adoption, from manufacturing bottlenecks to challenges in regulation and reimbursement.